Physician profile
Daniel Clement
NPI 1073977997
$1,812.71
in general payments reported to CMS, 2019-2025
12 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,093 · 2024: $132 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014 · Travel and Lodging: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.63 |
| Travel and Lodging | $799.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,236.67 | 2023-2025 | Inspire |
| Verona Pharma, INC. | $153.65 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $133.15 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $55.17 | 2024-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $49.36 | 2025 | Tezspire |
| Pulmonx Corporation | $47.09 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $29.81 | 2025 | |
| Jazz Pharmaceuticals INC. | $27.01 | 2025 | |
| Lilly USA, LLC | $22.79 | 2025 | Zepbound |
| United Therapeutics Corporation | $20.92 | 2025 | Tyvaso |
| Resmed Corp | $20.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.70 | 2025 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.